


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on October 31, 2007.



Frank C. Eisenschenk, Ph.D., Patent Attorney

RESPONSE UNDER 37 C.F.R. § 1.114  
Examining Group 1617  
Patent Application  
Docket No. MET-037CXT  
Serial No. 09/900,364

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Leonard M. Williams  
Art Unit : 1617  
Applicants : Paul D. van Poelje, Mark D. Erion, Toshihiko Fujiwara  
Serial No. : 09/900,364  
Filed : July 5, 2001  
Conf. No. : 7049  
For : Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

RESPONSE UNDER 37 C.F.R. § 1.114

Sir:

The remarks that follow are submitted for the Examiner's consideration in the above-referenced patent application in response to the Office Action dated October 22, 2007.